Analysts’ Top Healthcare Picks: GeneDx Holdings (WGS), Zymeworks (ZYME)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GeneDx Holdings (WGS – Research Report) and Zymeworks (ZYME – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GeneDx Holdings (WGS)
In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on GeneDx Holdings, with a price target of $153.00. The company’s shares closed last Wednesday at $85.10.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
Currently, the analyst consensus on GeneDx Holdings is a Strong Buy with an average price target of $154.13, representing a 74.7% upside. In a report issued on March 2, TipRanks – Google also upgraded the stock to Buy with a $90.00 price target.
See today’s best-performing stocks on TipRanks >>
Zymeworks (ZYME)
Bloom Burton analyst David Martin PhD maintained a Buy rating on Zymeworks today and set a price target of $35.00. The company’s shares closed last Wednesday at $25.14.
According to TipRanks.com, PhD is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zymeworks with a $39.75 average price target, representing a 58.4% upside. In a report issued on February 25, Citi also maintained a Buy rating on the stock with a $35.00 price target.
